کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5667111 | 1591745 | 2017 | 6 صفحه PDF | دانلود رایگان |
- To assess safety and effectiveness of sofosbuvir and simeprevirâ±âribavirin on HCV- and HIV/HCV-infected patients
- No significant difference between the two groups in rates of sustained virological response (SVR)
- A baseline platelet count â¥90 000/mm3 was associated with higher rates of SVR.
- SOFâ+âSMVâ±âRBV was associated with good safety and high SVR rates both in HCV- and HIV/HCV-infected individuals.
The combination of sofosbuvir and simeprevirâ±âribavirin (SOFâ+âSMVâ±âRBV) for hepatitis C virus (HCV) treatment has been associated with high rates of sustained virological response (SVR). Few data are available regarding this regimen in HIV/HCV co-infected patients. This study evaluated the effectiveness and safety of a 12-week course of SOFâ+âSMVâ±âRBV in a cohort of HCV monoinfected and HIV/HCV co-infected individuals. HCV-infected patients, with or without HIV infection, receiving a 12-week course of SOFâ+âSMVâ±âRBV in four Italian centres from February to October 2015, were included in this retrospective observational study. Clinical and biochemical data were retrieved for all patients. A total of 88 individuals were evaluated: 29 (33.0%) HIV/HCV co-infected and 59 (67.0%) monoinfected. Most patients were males with HCV genotype 1b (62.5%) and 1a (25%) infection. RBV was used in 41 HCV monoinfected and 6 HIV/HCV co-infected patients. Cirrhosis was found in 67 patients (76.1%). The most common adverse events (AEs) were rash and/or pruritus (23.9%), fatigue (13.6%) and anaemia (9.1%). Serious AEs occurred in three patients (3.4%). No treatment discontinuations were observed. RBV use was associated with multiple AEs (Pâ=â0.02). An overall SVR12 of 93.2% was achieved; 96.6% in HCV monoinfected and 86.2% in HIV/HCV co-infected individuals, without significance both in univariate (Pâ=â0.09) and multivariate analyses (Pâ=â0.12). A baseline platelet count â¥90 000/mm3 was associated with higher rates of SVR (Pâ=â0.005). A 12-week course of SOFâ+âSMVâ±âRBV was associated with good safety and high SVR12 rate both in HCV monoinfected and HIV-HCV co-infected individuals.
Journal: International Journal of Antimicrobial Agents - Volume 49, Issue 3, March 2017, Pages 296-301